Dr Brigida Maiorano discusses with ecancer the preliminary survival outcomes and biomarker analyses from the SURE-01 trial.

This phase II study evaluates neoadjuvant sacituzumab govitecan (SG) monotherapy followed by radical cystectomy (RC) in patients with muscle-invasive urothelial carcinoma of the bladder (MIBC).

The interim analysis demonstrated encouraging survival metrics. 

While neither survival estimates nor transcriptomic profiles showed a direct correlation with pathological response (the study’s interim endpoint) emerging data suggest that molecular subtypes and TOP1 gene expression may serve as putative predictive biomarkers of sacituzumab govitecan efficacy.